Nab‐paclitaxel‐based compared to docetaxel‐based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck
Amy E. Schell(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Kathryn Trinkaus(Washington University in St. Louis), Brian Nussenbaum(Washington University in St. Louis), Ningying Wu(Washington University in St. Louis), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), Hiram A. Gay(Washington University in St. Louis), Jason Diaz(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Loren S. Michel(Memorial Sloan Kettering Cancer Center), James S. Lewis(Vanderbilt University Medical Center)
Cited by 30
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532